The company has operations in over 60 countries, with headquarters in the UK, Singapore, Dubai and Amsterdam, and sales in almost 200 countries. The Company employs approximately 38,000 people worldwide. For more information visit www.rb.com
About Schiff Schiff's vitamin, minerals and supplements (VMS) product portfolio includes a number of market leading brands in the specialist product category in the USA, including MegaRed®, number 1 in the healthy heart segment, Move Free® the number 2 in joint care, Airborne® the number 2 in immune support, and Schiff Vitamins®.
Forward-Looking Statements Statements herein regarding the proposed transaction between Reckitt Benckiser and Schiff, future financial and operating results and any other statements about future expectations constitute "forward looking statements." These forward looking statements may be identified by words such as "believe," "expects," "anticipates," "projects," "intends," "should," "estimates" or similar expressions. Such statements are based upon current beliefs and expectations and are subject to significant risks and uncertainties. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward looking statements. We believe these forward-looking statements are reasonable; however, undue reliance should not be placed on any forward-looking statements, which are based on current expectations. All written and oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by these cautionary statements. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time unless required by law.
Important Additional Information This document is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities. The solicitation and offer to buy the common stock of Schiff will only be made pursuant to an offer to purchase and related materials that the acquirer filed with the Securities and Exchange Commission on November 16, 2012, as those materials may be amended. Stockholders should read these materials carefully because they contain important information, including the terms and conditions of the offer. Stockholders may obtain the offer to purchase and related materials with respect to the tender offer free of charge at the SEC's website at www.sec.gov or from MacKenzie Partners, Inc., Reckitt Benckiser's Information Agent, at 800-322-2885 (toll-free) or at +1-212-929-5500 (call collect).Investor & Analyst Contacts: Reckitt Benckiser (RB) United Kingdom Richard Joyce Director, Investor Relations +44 1753 217800 Media Contacts: United States Sard Verbinnen & Co (+1 212 687-8080) Jim Barron (+1 646 625-9145) Jared Levy (+1 617 233-1172) Brooke Gordon (+1 917 570-9176) United Kingdom Reckitt Benckiser (RB) Andraea Dawson-ShepherdSVP, Global Corporate Communication & Affairs+44 1753 446447 SOURCE Reckitt Benckiser Group PLC